Aug 01, 2025 • Motley Fool
SOMEWHAT-BULLISH
Glaukos ( GKOS ) Q2 Revenue Jumps 30%
Glaukos ( NYSE:GKOS ) , a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of $124.1 million, beating analyst expectations of $115.5 million by 7.4%.
Jul 31, 2025 • Zacks Commentary
NEUTRAL
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Jul 30, 2025 • Zacks Commentary
NEUTRAL
Glaukos ( GKOS ) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of +7.69% and +8.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 09, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.
Jun 16, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
What Makes Glaukos ( GKOS ) a New Buy Stock
Glaukos (GKOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Jun 11, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Can Glaukos ( GKOS ) Climb 34.4% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Glaukos (GKOS) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.